KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Long-Term Debt Repayments (2016 - 2026)

Amgen has reported Long-Term Debt Repayments over the past 16 years, most recently at $833.0 million for Q1 2026.

  • For Q1 2026, Long-Term Debt Repayments fell 66.68% year-over-year to $833.0 million; the TTM value through Mar 2026 reached $3.3 billion, down 45.36%, while the annual FY2025 figure was $5.0 billion, 38.89% up from the prior year.
  • Long-Term Debt Repayments for Q1 2026 was $833.0 million at Amgen, down from $1.5 billion in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $2.5 billion in Q1 2025 and troughed at $704.0 million in Q1 2023.
  • A 4-year average of $1.4 billion and a median of $1.2 billion in 2024 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: skyrocketed 193.33% in 2024 and later tumbled 66.68% in 2026.
  • Year by year, Long-Term Debt Repayments stood at $750.0 million in 2023, then surged by 193.33% to $2.2 billion in 2024, then tumbled by 31.82% to $1.5 billion in 2025, then plummeted by 44.47% to $833.0 million in 2026.
  • Business Quant data shows Long-Term Debt Repayments for AMGN at $833.0 million in Q1 2026, $1.5 billion in Q3 2025, and $1.0 billion in Q2 2025.